Gene associated with regulation of adiposity and insulin response
View Patent ↗This invention pertains to the identification and isolation of a gene implicated in the fatty liver dystrophy (fld) phenotype. Mouse and human forms of the novel gene, designated herein as Lpin1/LPIN1 (mouse and human genes, respectively), are identified. This invention additionally provides methods of screening for agents that alter adipose tissue development. The methods involve contacting a cell containing a Lpin1 gene with a test agent; and detecting a change in the expression or activity of a Lpin1 gene product, where a difference in the expression or activity of Lpin1 in the contacted cell indicates that the agent alters or is likely to alter adipose tissue development. Also provided are methods of identifying Lpin1 mutations, and methods of mitigating symptoms of lipodystrophy, obesity, diabetes, atherosclerosis and related pathologies.
1. A method of screening for an agent that alters adipose tissue development said method comprising:
contacting a cell comprising a Lpin1 gene encoding a polypeptide comprising an NLIP domain and a CLIP domain, with a test agent; and
detecting a change in the expression or activity of a Lpin1 gene product as compared to the expression or activity of a Lpin1 gene product in a cell that is contacted with the test agent at a lower concentration, where a difference in the expression or activity of said Lpin1 gene product in the contacted cell and the cell that is contacted with the lower concentration indicates that said agent alters adipose tissue development.
2. The method of claim 1 , wherein said lower concentration is the absence of said test agent.
3. The method of claim 1 , wherein the amount of Lpin1 gene product is detected by detecting Lpin1 mRNA in said sample.
4. The method of claim 3 , wherein said level of Lpin1 mRNA is measured by hybridizing said mRNA to a probe that specifically hybridizes to a Lpin1 nucleic acid.
5. The method of claim 4 , wherein said hybridizing is according to a method selected from the group consisting of a Northern blot, a Southern blot using DNA derived from the Lpin1 RNA, an array hybridization, an affinity chromatography, and an in situ hybridization.
6. The method of claim 4 , wherein said probe is a member of a plurality of probes that forms an array of probes.
7. The method of claim 3 , wherein the level of Lpin1 mRNA is measured using a nucleic acid amplification reaction.
8. The method of claim 1 , wherein said cell is cultured ex vivo.
9. The method of claim 1 , wherein said test agent is contacted to an animal comprising a cell containing the Lpin1 nucleic acid or the lipin protein.
10. A method of prescreening for an agent that alters adipose tissue development, said method comprising:
i) contacting a Lpin1 nucleic acid encoding a polypeptide comprising an NLIP domain and a CLIP domain with a test agent; and
ii) detecting specific binding of said test agent to said nucleic acid.
11. The method of claim 10 , further comprising recording test agents that specifically bind to said Lpin1 nucleic acid in a database of candidate agents that alter adipose tissue development.
12. The method of claim 10 , wherein said test agent is not a nucleic acid.
13. The method of claim 10 , wherein said binding is detected using a method selected from the group consisting of a Northern blot, a Southern blot using DNA derived from a Lpin1 RNA, an array hybridization, an affinity chromatography, and an in situ hybridization.
14. The method of claim 10 , wherein said test agent is contacted directly to the Lpin1 nucleic acid.
15. The method of claim 10 , wherein said test agent is contacted to a cell containing the Lpin1 nucleic acid.
16. The method of claim 15 , wherein said cell is cultured ex vivo.
17. The method of claim 10 , wherein said test agent is contacted to an animal comprising a cell containing the Lpin1 nucleic acid.